Cartoons Saturday's political cartoons include how much to pay for a pardon, medical advice from a brain worm, and a simple solution to the national debt.

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

The researchers obtained data on 35 individuals from the University of California San Francisco (UCSF) Adult Glioma Study,which recruited glioma cases and controls from 1991 through 2013 to ...

The glioma tumors from 17 individuals (with an average fire-fighting history of 22 years) were compared with those from 18 individuals in non-firefighting occupations.

Fractionated reirradiation is safe for recurrent high-grade glioma, with a median dose of 41.4 Gy and no critical structure injuries observed. Improved overall survival correlates with better ...

Cartoon Network is about to bring back some of their rarest shows to TV screens with a new update to Adult Swim’s Checkered Past block of Cartoon Network classics. Adult Swim began expanding its ...

The emergence of vorasidenib, the first targeted therapy for certain gliomas with IDH mutations, has ignited a wave of excitement in both patient and physician spaces. But following the approval ...

Inevitable progression Gliomas arise from glial cells, which protect and support a healthy nervous system. A substantial proportion of glioma cases are caused by mutations in IDH. "Patients ...

Glioma is a broad category of brain and spinal cord tumors that come from glial cells - brain cells that support nerve cells. The symptoms, prognosis, and treatment of a glioma depend on the ...

Pixclara, a glioma-imaging agent, has been granted priority review by the FDA with a decision deadline of April 26, 2025. The agent targets LAT and LAT2 proteins, aiding in distinguishing glioma ...

More information: Ilon Liu et al, GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant, Cancer Cell (2024). DOI: 10.1016/j ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first ...